ICT asked Loretta Litz Fauerbach, MS, FSHEA, FAPIC, CIC, of Fauerbach & Associates, LLC, about the imperatives relating to infection preventionists' grasp of clinical microbiology in their HAI-prevention work.
By Kelly M. Pyrek
Diekema and Saubolle (2011) remind us that "Preventing infections requires the ability to detect them when they occur, which is why the clinical microbiology laboratory (CML) plays a key role in healthcare-associated infection (HAI) prevention."
The quantity and quality of antibodies recognizing the end region of the malaria parasite's CSP protein is a good marker of protection by the RTS,S/AS01E vaccine, shows a study led by the Barcelona Institute for Global Health (ISGlobal) - an institution supported by "la Caixa"- in collaboration w
Dengue is on the rise, with about 20,000 patients dying each year from this mosquito-borne disease, yet despite ongoing efforts a broadly effective dengue vaccine is not available.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs).
A country’s progress toward measles elimination can be mapped on a “canonical path” that in turn can guide vaccination strategies, according to a study from scientists at the Johns Hopkins Bloomberg School of Public Health.
Chlamydia is the most prevalent bacterial sexually transmitted infection (STI) in the world. There is no vaccine to prevent infection.
In a breakthrough that could lead to a simple and inexpensive test for Ebola virus disease, researchers have generated two antibodies to the deadly virus.
The Food and Drug Administration (FDA) announces the approval of Dengvaxia, the first vaccine approved for the prevention of dengue disease caused by all dengue virus serotypes (1, 2, 3 and 4) in people ages 9 through 16 who have laboratory-confirmed previous dengue infection and who live in ende